Instil Bio’s Phase 2 trial of asset AXN-2510 to complete enrollment in China

Instil Bio (TIL) and ImmuneOnco announced clinical trial updates of AXN-2510 and NSCLC clinical development strategy. The companies anticipate sharing further clinical data in the second half of 2025. ImmuneOnco expects to complete enrollment of approximately 60 patients in Q3 2025 in its Phase 2 trial of ‘2510 in combination with chemotherapy in patients with NSCLC in the first-line setting in China. Among more than 30 NSCLC patients enrolled, more than 20 first-line NSCLC patients have been treated since the end of March. The objective response rate is similar to datasets from competitor PD-(L)1xVEGF bispecific antibodies at a similar stage of development in patients with previously treated NSCLC, showing ORR of 23%. The updated clinical safety from the full ‘2510 monotherapy trial and efficacy data in NSCLC are further detailed in a new corporate deck posted on Instil Bio’s investor relations webpage at https://ir.instilbio.com/news-events/presentations. Instil’s Phase 1b/2 trial of ‘2510 in the United States is expected to be initiated before the end of 2025, assuming necessary regulatory approvals. Instil believes that this may accelerate the path to initiating a potential global Phase 3 trial in first-line NSCLC.